Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03376893 · ClinicalTrials.gov registry record
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
A clinical trial of Stroke and Sickle Cell Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- 102
- Enrollment target
- 4
- Study locations
NCT03376893 is a study of Stroke and Sickle Cell Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 102 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03376893, a study of Stroke and Sickle Cell Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 4
- Study locations
Study Summary
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US. Silent and overt strokes contribute significantly to morbidity in adults with SCD, resulting in functional impairment, challenges with school and job performance, and premature death. Five NIH-funded randomized controlled trials have identified therapies to prevent silent and overt strokes in children with SCD, including monthly blood transfusion therapy (for preventing initial and recurrent strokes) and hydroxyurea (for preventing initial strokes). Despite the observation that at least 99% of children with SCD in high-income countries reach adulthood, and approximately 60% of adults will experience one or more strokes (\~50% with silent strokes and \~10% with overt strokes), no stroke trials have established therapeutic approaches for adults with SCD. For adults with SCD, inadequate evidence-based guidelines exist for secondary stroke prevention strategies. Applying stroke prevention strategies in children may not be effective for stroke prevention in adults with SCD, particularly given the high rate of co-morbidities. Identifying subgroups of adults with SCD and higher incidence coupled with the contribution of established stroke risk factors in the general population (smoking, diabetes, obesity, renal disease) will provide the requisite data required for the first-ever phase III clinical trials focused on secondary stroke prevention in adults.
Conditions Studied
Study Locations (4)
Tennessee
- Vanderbilt University Medical Center - Nashville
- Vanderbilt University Medical Center - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03376893
The ClinicalTrials.gov registry entry for NCT03376893 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT03376893 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Tennessee, Alabama, Missouri.
Frequently Asked Questions
What is clinical trial NCT03376893 about?
NCT03376893 is a clinical study titled "Epidemiology of Silent and Overt Strokes in Sickle Cell Disease". Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US. Silent and overt strokes contribute significantly to morbidity in adults with SCD, resulting in functional impairment, challenges with school and job performance, and pre...
What is the current status of trial NCT03376893?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2017-06-02. Estimated completion is 2026-12-31.
What conditions does trial NCT03376893 study?
This clinical trial studies the following conditions: Stroke, Sickle Cell Disease, Anemia, Sickle Cell, Sickle Cell Thalassemia, Sickle Cell-Beta0-Thalassemia.
Who is sponsoring clinical trial NCT03376893?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03376893 being conducted?
This trial has 4 study locations across Alabama, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.